These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 25211450)
1. Aggressive pituitary lesion with a remarkably high Ki-67. Marques P; Mafra M; Calado C; Martins A; Monteiro J; Leite V Arq Bras Endocrinol Metabol; 2014 Aug; 58(6):656-60. PubMed ID: 25211450 [TBL] [Abstract][Full Text] [Related]
2. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma? Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771 [TBL] [Abstract][Full Text] [Related]
3. A Case of Pituitary Carcinoma Initially Diagnosed as an Ectopic Growth Hormone Producing Pituitary Adenoma with a High Ki-67 Labeling Index. Endo T; Ogawa Y; Watanabe M; Tominaga T J Neurol Surg A Cent Eur Neurosurg; 2018 Jan; 79(1):90-95. PubMed ID: 28586933 [TBL] [Abstract][Full Text] [Related]
4. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas. Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566 [TBL] [Abstract][Full Text] [Related]
5. Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report. Guastamacchia E; Triggiani V; Tafaro E; De Tommasi A; De Tommasi C; Luzzi S; Sabbà C; Resta F; Terreni MR; Losa M Minerva Endocrinol; 2007 Sep; 32(3):231-6. PubMed ID: 17912159 [TBL] [Abstract][Full Text] [Related]
7. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. Kaltsas GA; Mukherjee JJ; Plowman PN; Monson JP; Grossman AB; Besser GM J Clin Endocrinol Metab; 1998 Dec; 83(12):4233-8. PubMed ID: 9851756 [TBL] [Abstract][Full Text] [Related]
8. ACTH-secreting Crooke cell carcinoma of the pituitary. Kovács GL; Góth M; Rotondo F; Scheithauer BW; Carlsen E; Saadia A; Hubina E; Kovács L; Szabolcs I; Nagy P; Czirják S; Hanzély Z; Kovács K; Horváth É; Korbonits M Eur J Clin Invest; 2013 Jan; 43(1):20-6. PubMed ID: 23134557 [TBL] [Abstract][Full Text] [Related]
9. Clinically aggressive phenotype: A clinicopathological case series of atypical pituitary adenomas. Lv L; Hu Y; Yin S; Wang M; Zhou P; Zhang N; Ma W; Zhang S; Jiang S Clin Neurol Neurosurg; 2018 Apr; 167():93-98. PubMed ID: 29471288 [TBL] [Abstract][Full Text] [Related]
10. Pituitary carcinoma in situ. Pasquel FJ; Vincentelli C; Brat DJ; Oyesiku NM; Ioachimescu AG Endocr Pract; 2013; 19(3):e69-73. PubMed ID: 23425649 [TBL] [Abstract][Full Text] [Related]
11. Refractory pituitary adenoma: a novel classification for pituitary tumors. Dai C; Feng M; Liu X; Ma S; Sun B; Bao X; Yao Y; Deng K; Wang Y; Xing B; Lian W; Zhong D; Ma W; Wang R Oncotarget; 2016 Dec; 7(50):83657-83668. PubMed ID: 27845901 [TBL] [Abstract][Full Text] [Related]
12. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912 [TBL] [Abstract][Full Text] [Related]
13. Low grade astrocytoma of the pituitary stalk. Yap L; Crooks D; Warnke P Acta Neurochir (Wien); 2007 Mar; 149(3):307-11; discussion 311-2. PubMed ID: 17242848 [TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
15. Cystic lesions of the pituitary: clinicopathological features distinguishing craniopharyngioma, Rathke's cleft cyst, and arachnoid cyst. Shin JL; Asa SL; Woodhouse LJ; Smyth HS; Ezzat S J Clin Endocrinol Metab; 1999 Nov; 84(11):3972-82. PubMed ID: 10566636 [TBL] [Abstract][Full Text] [Related]
16. Prothymosin-alpha and Ki-67 expression in pituitary adenomas. Wierzbicka-Tutka I; Sokołowski G; Bałdys-Waligórska A; Adamek D; Radwańska E; Gołkowski F Postepy Hig Med Dosw (Online); 2016 Nov; 70(0):1117-1123. PubMed ID: 27892895 [TBL] [Abstract][Full Text] [Related]
17. [Pituitary atypical adenoma or malignant corticotrophinoma?]. Alves M; Paiva I; Belo F; Rebelo O; Bastos M; Carvalheiro M Acta Med Port; 2011 Dec; 24 Suppl 3():661-6. PubMed ID: 22856408 [TBL] [Abstract][Full Text] [Related]
18. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry]. Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431 [TBL] [Abstract][Full Text] [Related]
19. [Primary Pituitary Malignant Lymphoma that was Difficult to Differentiate from Nonfunctioning Pituitary Adenoma:A Case Report]. Murakami Y; Sato T; Jinguji S; Kishida Y; Watanabe T; Suzuki O; Ikeda K; Homma M; Midorikawa S; Saito K No Shinkei Geka; 2016 Sep; 44(9):779-84. PubMed ID: 27605481 [TBL] [Abstract][Full Text] [Related]
20. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness. Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]